A Phase I Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian Cancer and Other Solid Tumours

NCT03427073 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

20

Enrollment

INDUSTRY

Sponsor class

Stopped to re-evaluate biomarker strategy for recruitment to Part 2

Conditions

Solid Tumors
Ovarian Cancer

Interventions

DRUG: ALM201

Sponsor

Almac Discovery